Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Eltrombopag (Primary) ; Azacitidine; Decitabine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 09 May 2019 Status changed from active, no longer recruiting to completed.
- 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology